Abacavir/lamivudine/zidovudine

From Wikipedia, the free encyclopedia
  (Redirected from Trizivir)
Jump to: navigation, search
Abacavir/lamivudine/zidovudine
Abacavir, lamivudine and zidovudine.svg
Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleoside analogue reverse transcriptase inhibitor
Zidovudine Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names Trizivir
AHFS/Drugs.com FDA Professional Drug Information
MedlinePlus a687007
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code J05AR04 (WHO)
Legal status
Legal status
Identifiers
CAS Number 364057-50-1 N
ChemSpider 21106400 YesY
NIAID ChemDB 058986
 NYesY (what is this?)  (verify)

Abacavir/lamivudine/zidovudine, sold under the trade name Trizivir, is a medication for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[2]

It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir.[5][6] As of 2015 the cost for a typical month of medication in the United States is more than 200 USD.[7]

See also[edit]

References[edit]

  1. ^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases. 185 (9): 1251–1260. doi:10.1086/340312. 
  2. ^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture Archived January 4, 2012, at the Wayback Machine.
  3. ^ Drugs.com: Trizivir
  4. ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV" (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297. 
  5. ^ Monthly Prescribing Reference (MPR)
  6. ^ Lupin Pharma
  7. ^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 60. ISBN 9781284057560.